Halaven - (1 mg/2 mL; Injection)

Generic Name	Eribulin	Innovator	EISAI INC
Dosage	1 mg/2 mL; Injection	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	HALAVEN is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******	*** \ *********	*** *, ****	********* ** ****** ** ******	****	******* *** **** *** *** ****
**** *****	** \ **	*** **, ****	********* ** ****** ** **** *****	****	******* *** **** *** *** ****
** *****'*	** \ **	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events